Genuinely effective obesity drugs, as GLP-1s appear to be, should have a positive impact on the bottom line of US health insurers like Cigna (CI), United Healthcare (UNH), Humana (HUM) and Centene (CNC) in the long term while harming companies paying for these very expensive and likely to be in-demand medications like Insperity (NSP) and Robert Half (RHI)
Phase 3 clinical trials are still underway, coming to a close in May 2026
Im hopeful. While GLP-1 drugs may have some potential benefits for people with psoriatic arthritis, there are also important concerns
Trimethylaminuria does not cause any other physical health problems, and people with the condition are usually in good health otherwise
These spots allow reliable absorption
Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells